or Try an Advanced Search...

    Technical Analysis for IMC - Immuron Limited  

    Grade Last Price % Change Price Change
    F 0.076 1.33% 0.001
    IMC closed unchanged on Wednesday, November 6, 2024, on 26 percent of normal volume. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    Earnings due: Nov 20
    *** please verify all earnings dates ***
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical IMC trend table...
    Date Alert Name Type % Chg
    Hammer Candlestick Bullish 1.33%
    Lizard Bullish Bullish Day Trade Setup 1.33%
    Doji - Bullish? Reversal 1.33%
    Oversold Stochastic Weakness 1.33%
    Gapped Down Weakness 1.33%
    Oversold Stochastic Weakness 1.33%
    MACD Bullish Signal Line Cross Bullish -2.56%
    Narrow Range Bar Range Contraction -2.56%
    Wide Bands Range Expansion -2.56%
    Oversold Stochastic Weakness -2.56%
    Older End-of-Day Signals for IMC ...

       Recent Intraday Alerts

    Alert Time
    Lizard Bullish Entry 3 minutes ago
    Hammer Candlestick Entry 3 minutes ago
    Rose Above Previous Day's High 3 minutes ago
    Up 1% 3 minutes ago
    Fell Below Previous Day's Low 2 days ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    IMC Chart by TradingView
    Basic chart:

    Profile

    Immuron Limited   Description

    Immuron Limited is a biopharmaceutical company. The Company focuses on the research and development of bovine-colostrum enriched with antibodies of choice for the treatment and prevention of a range of infections and immune modulated diseases. The Company has three segments: Research and Development (R&D), HyperImmune Products and Corporate. The R&D segment focuses on the Company's research and development projects performed in Australia and Israel. The Company sells and licenses its product, Travelan. The HyperImmune Products segment is engaged in its Travelan product's activities, which occur in Australia, New Zealand and Canada. The Corporate segment's activities primarily occur in Australia. It also develops products for applications, including non-alcoholic steatohepatitis (NASH), alcoholic steatohepatitis (ASH) and clostridium difficile (C-Diff), diabetes, colitis and uropathogenic escherichia coli (UPEC). The Company also offers Protectyn, IMM 124-E-NASH and IMM 529-CDI.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Pharmaceutical Disease Travel Diseases Biopharmaceutical Medical Specialties Prevention Infection Diabetes Infectious Diseases Hepatitis Infections Antibodies Colostrum Steatohepatitis

    Is IMC a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Oct 29 Presenting on the Emerging Growth Conference 76 Day 1 on October 30 Register Now
    Oct 16 Immuron CEO, Steven Lydeamore participation in Maxim Virtual Healthcare Conference
    Oct 15 Immuron Travelan® continued strong sales growth
    Oct 4 NMRC Reports Results for Campylobacter Controlled Human Infection Model Study
    Oct 3 Immuron Full Year 2024 Earnings: AU$0.03 loss per share (vs AU$0.017 loss in FY 2023)
    Sep 24 Presenting on the Emerging Growth Conference 75 Day 1 on September 25 Register Now
    Sep 5 Immuron Plans Phase 2 Trial for IMM-529 following FDA review
    Aug 21 Presenting on the Emerging Growth Conference 74 Day 2 on August 22 Register Now
    Aug 19 US DoD grants $2.3m to Immuron for military version of anti-diarrhoeal Travelan
    Aug 16 Immuron Announces New U.S. Department of Defense Research Award for Naval Medical Research Command and Walter Reed Army Institute of Research to advance Travelan®
    See more IMC news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 0.17
    52 Week Low 0.065
    Average Volume 263,075
    200-Day Moving Average 0.092
    50-Day Moving Average 0.093
    20-Day Moving Average 0.080
    10-Day Moving Average 0.077
    Average True Range 0.003
    RSI (14) 30.56
    ADX 27.77
    +DI 17.687
    -DI 42.630
    Chandelier Exit (Long, 3 ATRs) 0.095
    Chandelier Exit (Short, 3 ATRs) 0.083
    Upper Bollinger Bands 0.088
    Lower Bollinger Band 0.072
    Percent B (%b) 0.18
    BandWidth 19.500
    MACD Line -0.005
    MACD Signal Line -0.005
    MACD Histogram 0.0001
    Fundamentals Value
    Market Cap 17.01 Million
    Num Shares 227 Million
    EPS -0.03
    Price-to-Earnings (P/E) Ratio -2.34
    Price-to-Sales 18.21
    Price-to-Book 10.45
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.078
    Resistance 3 (R3) 0.078 0.076 0.078
    Resistance 2 (R2) 0.076 0.076 0.077 0.077
    Resistance 1 (R1) 0.076 0.075 0.076 0.076 0.077
    Pivot Point 0.074 0.074 0.075 0.075 0.074
    Support 1 (S1) 0.074 0.074 0.074 0.074 0.073
    Support 2 (S2) 0.072 0.073 0.073 0.073
    Support 3 (S3) 0.072 0.072 0.073
    Support 4 (S4) 0.072